GSSC - ETF AI Analysis
Top Page
Goldman Sachs Activebeta U.S. Small Cap Equity ETF (GSSC)
GSSC, the Goldman Sachs Activebeta U.S. Small Cap Equity ETF, has a solid overall rating driven largely by strong holdings like CareDx and Alkermes, which show robust revenue growth, improving profitability, and positive earnings call sentiment. Retail names such as Abercrombie & Fitch and Victoria’s Secret also support the fund with strong earnings and guidance, while weaker positions like Travere Therapeutics, which faces high leverage and profitability challenges, slightly weigh on the rating. The main risk factor is the fund’s exposure to smaller, often less profitable companies, which can make performance more volatile even when technical momentum is positive.
GSSC vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.05B
- Region
- North America
- Expense Ratio
- 0.20%
- Beta
- 0.99
- Issuer
- Goldman Sachs
- Inception Date
- Jun 28, 2017
- Dividend Yield
- 1.00%
- Asset Class
- Equity
- Index Tracked
- Goldman Sachs ActiveBeta US Small Cap Equity
GSSC Summary
GSSC is an exchange-traded fund from Goldman Sachs that follows the Goldman Sachs ActiveBeta US Small Cap Equity index, focusing on smaller U.S. companies with room to grow. It spreads investments across many sectors like health care, financials, and technology, and holds names such as Alkermes and 10x Genomics. Investors might consider GSSC to add growth potential and diversification, since small-cap stocks can sometimes outperform larger, more established companies. However, small-cap stocks can be more volatile, so the value of this ETF can go up and down more sharply with the market.
How much will it cost me?
GSSC has an expense ratio of 0.20%, which means you’ll pay about $2 per year for every $1,000 invested. This cost is slightly higher than the cheapest index ETFs but still reasonable, because it uses an actively managed, multi-factor strategy rather than a simple passive index approach.
What would affect this ETF?
GSSC could benefit if the U.S. economy stays healthy and small-cap companies in sectors like health care, financials, and technology continue to grow, especially as its active, multi-factor strategy may help it adapt to changing market conditions. On the downside, rising interest rates, tighter credit, or regulatory changes in health care and financial services could hurt smaller companies more than large ones, making this ETF more volatile during economic slowdowns.
GSSC Top 10 Holdings
GSSC leans heavily into U.S. small-cap health care, and that’s where much of the action is. High-momentum names like 10x Genomics, CareDx, and Atricure are helping power returns, reflecting rising optimism around innovative therapies and medical devices. On the flip side, Alkermes and Travere Therapeutics are more mixed, with profitability concerns and regulatory uncertainty occasionally putting a lid on gains. Outside of health care, Victoria’s Secret adds a consumer twist with steadier progress, but overall this fund’s story is a domestically focused, small-cap health care engine with a few diversified sidecars.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TXG | 10x Genomics | 0.59% | $6.15M | $9.31B | 468.92% | 60Neutral |
 CDNA | CareDx | 0.56% | $5.86M | $3.58B | 374.51% | 77Outperform |
 ALKS | Alkermes | 0.35% | $3.66M | $7.40B | 42.10% | 80Outperform |
 AAMI | Acadian Asset Management | 0.35% | $3.65M | $3.38B | 96.71% | 66Neutral |
 ZETA | Zeta Global Holdings Corp | 0.33% | $3.49M | $8.56B | 81.68% | 67Neutral |
 ATRC | Atricure | 0.30% | $3.19M | $2.93B | 59.80% | 71Outperform |
 TVTX | Travere Therapeutics | 0.30% | $3.19M | $4.93B | 90.79% | 56Neutral |
 ENVA | Enova International | 0.30% | $3.10M | $4.48B | 55.14% | 71Outperform |
 DAVE | Dave | 0.29% | $3.04M | $4.64B | 75.14% | 80Outperform |
GSSC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSSC, the sentiment is Positive. The current price of 86.59 is above the 20-day moving average (MA) of 86.09, below the 50-day MA of 88.18, and above the 200-day MA of 83.86, indicating a neutral trend. The MACD of -0.65 indicates Negative momentum. The RSI at 48.64 is Neutral, neither overbought nor oversold. The STOCH value of 64.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSSC.
GSSC Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GSSC | $86.59 | $92.00(6.25% Upside) | $1.05B | 0.20% | 64Neutral |
 FNDA | $35.84 | $43.77(22.13% Upside) | $8.81B | 0.25% | 68Neutral |
 FESM | $45.21 | $60.22(33.21% Upside) | $6.61B | 0.28% | 64Neutral |
 SMLF | $84.70 | $108.64(28.27% Upside) | $4.15B | 0.15% | 66Neutral |
 VIOO | $129.06 | $159.23(23.38% Upside) | $4.06B | 0.07% | 66Neutral |
 CALF | $58.45 | $63.93(9.38% Upside) | $3.74B | 0.59% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GSSC | Goldman Sachs Activebeta U.S. Small Cap Equity ETF | 86.59 | 11.09 | 14.70% | |
| FNDA | Schwab Fundamental US Small Co. Index ETF | 35.84 | 4.74 | 15.23% | |
| FESM | Fidelity Enhanced Small Cap ETF | 45.21 | 7.81 | 20.89% | |
| SMLF | iShares MSCI USA Small-Cap Multifactor ETF | 84.70 | 9.99 | 13.37% | |
| VIOO | Vanguard S&P Small-Cap 600 ETF | 129.06 | 17.77 | 15.96% | |
| CALF | Pacer US Small Cap Cash Cows 100 ETF | 58.45 | 15.10 | 34.84% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.